| Status | Study |
| Recruiting |
Study Name: Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Condition: Hodgkin Disease Lymphoma, Large-Cell, Anaplastic Date: 2016-10-18 Interventions: Drug: Brentuximab Vedotin Brentuximab vedotin IV infusion. |
| Recruiting |
Study Name: Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK + Condition: ALCL Date: 2016-09-07 Interventions: Other: Blood sample |
| Not yet recruiting |
Study Name: Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma Condition: Anaplastic Large Cell Lymphoma, ALK-Positive Systemic Date: 2016-03-29 Interventions: Drug: Brentuximab Vedotin Give |
| Withdrawn |
Study Name: A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib Condition: Systemic Anaplastic Large-Cell Lymphoma Date: 2015-06-30 Interventions: Drug: crizotinib crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vinc |
| Recruiting |
Study Name: Brentuximab Vedotin and Imatinib in Patients With Relapsed or Refractory ALK+ ALCL Condition: ALK+ Anaplastic Large Cell Lymphoma Date: 2015-05-18 Interventions: Drug: Brentuximab vedotin Bren |
| Recruiting |
Study Name: Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas Condition: Anaplastic Large Cell Lymphoma, ALK-Positive Date: 2015-04-03 Interventions: Drug: crizotinib |
| Recruiting |
Study Name: Brentuximab Vedotin (Recombinant) for IV Infusion - Special Drug Use Surveillance (All-case Surveillance) "Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma" Condition: Relapsed or Refractory CD30+ Hodgkin's Lymphoma or Anaplastic Large Cell Lymphoma Date: 2014-04-17 Interventions: Drug: Brentuximab vedotin (recombinant) Brentuximab vedotin (recombinant) for IV infusion |
| Suspended |
Study Name: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma Condition: Anaplastic Large Cell Lymphoma, ALK-Positive CD30-Positive Neop Date: 2013-11-04 Interventions: Drug: Brentuximab Vedotin Give |
| Completed |
Study Name: A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma Condition: Hodgkin Lymphoma Anaplastic Large-cell Lymphoma Date: 2013-09-23 Interventions: Drug: brentuximab vedotin Bren |
| Active, not recruiting |
Study Name: Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma Condition: Anaplastic Large-cell Lymphoma Date: 2013-07-01 Interventions: Drug: brentuximab vedotin Brentuximab vedotin will be administered as a single intravenous (IV) infusion |